1887

Chapter 11 : Treatment and Prophylaxis of Gastroenteritis

Author: Michael L. Bennish1
VIEW AFFILIATIONS HIDE AFFILIATIONS
Affiliations: 1: Africa Centre for Health and Population Studies, Mtubatuba, South Africa
Content Type: Monograph
Publication Year: 2003

Category: Clinical Microbiology

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Preview Magnify
Zoom in
Zoomout

Treatment and Prophylaxis of Gastroenteritis, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap11-1.gif /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap11-2.gif

Abstract:

This chapter reviews the characteristics of the quinolones that make them useful for the treatment of enteric infections, and the role of these agents in treating enteric infections. There are a limited number of case reports of quinolones causing arthralgia when used for longer periods. The majority of these have been in children with cystic fibrosis, which is known to be associated with arthralgia, or with the prolonged use of pefloxacin, which is the most potent of the quinolones in initiating arthropathy in animals. The chapter reviews the indications for quinolone use in specific enteric infections or clinical conditions. The study in which patients had the shortest duration of illness, however, was the only one that did not show a reduction in diarrhea duration. The efficacy of antimicrobial prophylaxis of traveler's diarrhea was well established by studies conducted starting in the 1970s with doxycycline, and then with trimethoprim-sulfamethoxazole. There have been at least six studies of fluoroquinolone prophylaxis of traveler's diarrhea. All six studies showed efficacy in reducing the incidence of diarrhea. The protection afforded by prophylaxis in these studies ranged from 76 to 100%, similar to what is found using nonquinolone agents. Still, if someone is going to a particularly high-risk area for a short time, prophylaxis with a fluoroquinolone is likely to markedly diminish the risk of traveler's diarrhea. is another putative cause of gastroenteritis, strains of which are almost all susceptible to quinolones.

Citation: Bennish M. 2003. Treatment and Prophylaxis of Gastroenteritis, p 193-216. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch11
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555817817.chap11
1. Acheson, D. W.,, and C. L. Sears. 2001. Dangers of empiric oral ciprofloxacin in the treatment of acute inflammatory diarrhea in children. Pediatr. Infect. Dis. J. 20: 817– 818.
2. Adachi, J. A.,, L. Ostrosky-Zeichner,, H. L. DuPont,, and C. D. Ericsson. 2000. Empirical antimicrobial therapy for traveler's diarrhea. Clin. Infect. Dis. 31: 1079– 1083.
3. Agalar, C.,, S. Usubutun,, E. Tutuncu,, and R. Turkyilmaz. 1997. Comparison of two regimens for ciprofloxacin treatment of enteric infections. Eur. J. Clin. Microbiol. Infect. Dis. 16: 803– 806.
4. Ahmad, F.,, G. Bray,, R. W. Prescott,, S. Aquilla,, and N. F. Lightfoot. 1991. Use of ciprofloxacin to control a Salmonella outbreak in a long-stay psychiatric hospital. J. Hosp. Infect. 17: 171– 178.
5. Ahmed, A.,, N. Salahuddin,, T. Ahsan,, S. Afsar,, N. Nasir,, S. Farooqui,, A. N. Chaoudri,, M. A. Akhtar,, I. Agha,, and N. Nagi. 1992. Enoxacin in the treatment of typhoid fever. Clin. Ther. 14: 825– 828.
6. Ait-Khaled, A.,, L. Zidane,, A. Amrane,, and R. Aklil. 1990. The efficacy and safety of pefloxacin in the treatment of typhoid fever in Algeria. J. Antimicrob. Chemother. 26: 181– 186.
7. Alam, M. N.,, S. A. Haq,, K. K. Das,, P. K. Baral,, M. N. Mazid,, R. U. Siddique,, K. M. Rahman,, Z. Hasan,, M. A. Khan,, and P. Dutta. 1995. Efficacy of ciprofloxacin in enteric fever: comparison of treatment duration in sensitive and multidrug-resistant Salmonella. Am. J. Trop. Med. Hyg. 53: 306– 311.
8. Alios, B. M. 2001. Campylobacter jejuni infections: update on emerging issues and trends. Clin. Infect. Dis. 32: 1201– 1206.
9. Alsoub, H.,, A. K. Uwaydah,, I. Matar,, M. Zebeib,, and K. M. Elhag. 1997. A clinical comparison of typhoid fever caused by susceptible and multidrug-resistant strains of Salmonella typhi. Br. J. Clin. Bract. 51: 8– 10.
10. Anders, B. J.,, B. A. Lauer,, J. W. Paisley,, and L. B. Reller. 1982. Double-blind placebo controlled trial of erythromycin for treatment of Campylobacter enteritis. Lancet. 1: 131– 132.
11. Angulo, F. J.,, K. R. Johnson,, R. V. Tauxe,, and M. L. Cohen. 2000. Origins and consequences of antimicrobial-resistant nontyphoidal Salmonella: implications for the use of fluoroquinolones in food animals. Microb. Drug Resist. 6: 77– 83.
12.Anonymous. 1995. Guidelines for the control of epidemics due to Shigella dysenteriae type 1 WHO/CDR/95.4. World Health Organization, Geneva, Switzerland.
13. Anonymous. 2002. Preliminary FoodNet data on the incidence of foodborne illnesses—selected sites, United States, 2001. Morb. Mortal. Wkly. Rep. 51: 325– 329.
14. Arnold, K.,, C. S. Hong,, R. Nelwan,, I. Zavala-Trujillo,, A. Kadio,, M. A. Barros,, and S. de Garis. 1993. Randomized comparative study of fleroxacin and chloramphenicol in typhoid fever. Am. J. Med. 94: 195S– 200S.
15. Asperilla, M. O.,, R. A. Smego, Jr.,, and L. K. Scott. 1990. Quinolone antibiotics in the treatment of Salmonella infections. Rev. Infect. Dis. 12: 873– 889.
16. Attar, A.,, B. Flourie,, J. C. Rambaud,, C. Franchisseur,, P. Ruszniewski,, and Y. Bouhnik. 1999. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology. 117: 794– 797.
17. Auckenthaler, R.,, M. Michea-Hamzehpour,, and J. C. Pechere. 1986. In-vitro activity of newer quinolones against aerobic bacteria. J.. Antimicrob. Chemother. 17: 29– 39.
18. Bahl, R.,, N. Bhandari,, M. K. Bhan,, M. Saxena,, and A. Bagati. 1996. Efficacy of antimicrobial treatment in nondysenteric persistent diarrhoea in a community setting. Acta Paediatr. 85: 1290– 1294.
19. Bassily, S.,, K. C Hyams,, N. A. el-Masry,, Z. Farid,, E. Cross,, A. L. Bourgeois,, E. Ayad,, and R. G. Hibbs. 1994. Shortcourse norfloxacin and trimethoprim-sulfamethoxazole treatment of shigellosis and salmonellosis in Egypt. Am. J. Trop. Med. Hyg. 51: 219– 223.
20. Beckebaum, S.,, J. Bircher,, and H. Gallenkamp. 1996. Bioavailability of ciprofloxacin in patients with acute infectious diarrhoe. Eur. J. Clin. Pharmacol. 50: 511– 512.
21. Bennish, M. L.,, J. R. Harris,, B. J. Wojtyniak,, and M. Struelens 1990. Death in shigellosis: incidence and risk factors in hospitalized patients. J. Infect. Dis. 161: 500– 506.
22. Bennish, M. L.,, M. A. Salam,, R. Haider,, and M. Barza. 1990. Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin. J. Infect. Dis. 162: 711– 716.
23. Bennish, M. L.,, M. A. Salam,, M. A. Hossain,, J. Myaux,, E. H. Khan,, J. Chakraborty,, F. Henry,, and C. Ronsmans. 1992. Antimicrobial resistance of Shigella isolates in Bangladesh, 1983-1990: increasing frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, and nalidixic acid. Clin. Infect. Dis. 14: 1055– 1060.
24. Bennish, M. L.,, M. A. Salam,, W. A. Khan,, and A. M. Khan. 1992. Treatment of shigellosis: III. Comparison of one- or two-dose ciprofloxacin with standard 5-day therapy. A randomized, blinded trial. Ann. Intern. Med. 117: 727– 734.
25. Bennish, M. L.,, and B. J. Wojtyniak 1991. Mortality due to shigellosis: community and hospital data. Rev. Infect. Dis. 13: S245– S251.
26. Bergan, T.,, S. Lolekha,, M. K. Cheong,, C. L. Poh,, S. Doencham,, and D. Charoenpipop. 1988. Effect of recent antibacterial agents against bacteria causing diarrhoea. Scand. J. Infect. Dis. Suppl. 56: 7– 10.
27. Bergan, T.,, S. Lolekha,, M. K. Cheong,, C. L. Poh,, and S. Patancharoen. 1988. Consequences of diarrhoeal disease on the pharmacokinetics of norfloxacin. Scand J. Infect. Dis. Suppl. 56: 11– 3.
28. Besser, R. E.,, P. M. Griffin,, and L. Slutsker. 1999. Escherichia coli 0157:H7 gastroenteritis and the hemolytic uremic syndrome: an emerging infectious disease. Annu. Rev. Med. 50: 355– 367.
29. Bethell, D. B.,, N. P. Day,, N. M. Dung,, C. McMullin,, H. T. Loan,, D. T. Tam,, L. T. Minh,, N. T. Linh,, N. Q. Dung,, H. Vinh,, A. P. MacGowan,, L. O. White,, and N. J. White. 1996. Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever. Antimicrob Agents Chemother. 40: 2167– 2172.
30. Bethell, D. B.,, T. T. Hien,, L. T. Phi,, N. P. Day,, H. Vinh,, N. M. Duong,, N. V. Len,, L. V. Chuong,, and N. J. White. 1996. Effects on growth of single short courses of fluoroquinolones. Arch. Dis. Child. 74: 44– 46.
31. Bhattacharya, K.,, M. K. Bhattacharya,, D. Dutta,, S. Dutta,, M. Deb,, A. Deb,, K. P. Das,, H. Koley,, and G. B. Nair. 1997. Double-blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children. Acta. Paediatr. 86: 319– 320.
32. Bhattacharya, M. K.,, G. B. Nair,, D. Sen,, M. Paul,, A. Debnath,, A. Nag,, D. Dutta,, P. Dutta,, S. C. Pal,, and S. K. Bhattacharya. 1992. Efficacy of norfloxacin for shigellosis: a double-blind randomised clinical trial. J. Diarrhoeal. Dis. Res. 10: 146– 150.
33. Bhattacharya, S. K.,, M. K. Bhattacharya,, P. Dutta,, D. Dutta,, S. P. De,, S. N. Sikdar,, A. Maitra,, A. Dutta,, and S. C. Pal. 1990. Double-blind, randomized, controlled clinical trial of norfloxacin for cholera. Antimicrob. Agents. Chemother. 34: 939– 940.
34. Bhattacharya, S. K.,, M. K. Bhattacharya,, P. Dutta,, D. Sen,, R. Rasaily,, A. Moitra,, and S. C. Pal. 1991. Randomized clinical trial of norfloxacin for shigellosis. Am. J. Trop. Med. Hyg. 45: 683– 687.
35. Bouckenooghe, A. R.,, Z. D. Jiang,, F. J. De La Cabada,, C. D. Ericsson,, and H. L. DuPont. 2002. Enterotoxigenic Escherichia coli as cause of diarrhea among Mexican Adults and US Travelers in Mexico. J. Travel Med. 9: 137– 140.
36. Bryan, J. P.,, C. Waters,, J. Sheffield,, R. E. Krieg,, P. L. Perine,, and K. Wagner 1990. In vitro activities of tosufloxacin, temafloxacin, and A-56620 against pathogens of diarrhea. Antimicrob. Agents Chemother. 34: 368– 370.
37. Burkhardt, J. E.,, J. N. Walterspiel,, and U. B. Schaad. 1997. Quinolone arthropathy in animals versus children. Clin. Infect. Dis. 25: 1196– 1204.
38. Butler, T.,, S. Lolekha,, C. Rasidi,, A. Kadio,, P. L. del Rosal,, H. Iskandar,, E. Rubinstein,, and G. Pastore. 1993. Treatment of acute bacterial diarrhea: a multicenter international trial comparing placebo with fleroxacin given as a single dose or once daily for 3 days. Am. J. Med. 94: 187S– 194S.
39. Cadamy, A. R. 1997. Treating diarrhoea. Patients must be educated about which symptoms require treatment. Br. Med. I.J. 315: 1378.
40. Cao, X. T.,, R. Kneen,, T. A. Nguyen,, D. L. Truong,, N. J. White,, and C. M. Parry. 1999. A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. The Dong Nai Pediatric Center Typhoid Study Group. Pediatr. Infect. Dis. J. 18: 245– 248.
41. Carlstedt, G.,, P. Dahl,, P. M. Niklasson,, K. Gullberg,, G. Banck,, and G. Kahlmeter. 1990. Norfloxacin treatment of salmonellosis does not shorten the carrier stage. Scand. J. Infect. Dis. 22: 553– 556.
42. Chew, S. K.,, E. H. Monteiro,, Y. S. Lim,, and D. M. Allen. 1992. A 7-day course of ciprofloxacin for enteric fever. J. Infect. 25: 267– 271.
43. Chin, N. X.,, and H. C. Neu. 1984. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 25: 319– 326.
44. Chinh, N. T.,, C. M. Parry,, N. T. Ly,, H. D. Ha,, M. X. Thong,, T. S. Diep,, J. Wain,, N. J. White,, and J. J. Farrar. 2000. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. Antimicrob. Agents Chemother. 44: 1855– 1859.
45. Chitnis, V.,, D. Chitnis,, S. Verma,, and N. Hemvani. 1999. Multidrug-resistant Salmonella typhi in India. Lancet 354: 514– 515.
46. Chu, Y. W.,, E. T. Houang,, D. J. Lyon,, J. M. Ling,, T. K. Ng,, and A. F. Cheng. 1998. Antimicrobial resistance in Shigella flexneri and Shigella sonnei in Hong Kong, 1986 to 1995. Antimicrob. Agents Chemother. 42: 440– 443.
47. Conrad, S.,, M. Oethinger,, K. Kaifel,, G. Klotz,, R. Marre,, and W. V. Kern. 1996. gyrA mutations in high-level fluoroquinolone- resistant clinical isolates of Escherichia coli. J. Antimicrob. Chemother. 38: 443– 455.
48. Cristiano, P.,, L. Imparato,, C. Carpinelli,, F. Lauria,, M. R. Iovene,, M. F. Corrado,, P. Maio,, and C. Imperatore. 1995. Pefloxacin versus chloramphenicol in the therapy of typhoid fever. Infection 23: 103– 106.
49. Cristiano, P.,, G. Morelli,, V. Briante,, M. R. Iovene,, F. Simioli,, and P. Altucci. 1989. Clinical experience with pefloxacin in the therapy of typhoid fever. Infection 17: 86– 87.
50. de la Cabada, F. J.,, H. L. DuPont,, K. Gyr,, and J. J. Mathewson. 1992. Antimicrobial therapy of bacterial diarrhea in adult residents of Mexico—lack of an effect. Digestion 53: 134– 141.
51. De Mol, P.,, T. Mets,, R. Lagasse,, J. Vandepitte,, A. Mutwewingabo,, and J. P. Butzler. 1987. Treatment of bacillary dysentery: a comparison between enoxacin and nalidixic acid. J. Antimicrob. Chemother. 19: 695– 698.
52. Diridl, G.,, H. Pichler,, and D. Wolf. 1986. Treatment of chronic salmonella carriers with ciprofloxacin. Eur. J. Clin. Microbiol. 5: 260– 261.
53. Doganci, L.,, H. Gun,, M. Baysallar,, A. Albay,, E. Cinar,, and T. Haznedaroglu 1995. Short-term quinolones for successful eradication of multiply resistant Vibrio cholerae in adult patients. Scand. J. Infect. Dis. 27: 425– 426.
54. Dryden, M. S.,, R. J. Gabb,, and S. K. Wright. 1996. Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin. Clin. Infect. Dis. 22: 1019– 1025.
55. DuPont, H. L.,, C. D. Ericsson,, J. J. Mathewson,, and M. W. DuPont. 1992. Five versus three days of ofloxacin therapy for traveler's diarrhea: a placebo-controlled study. Antimicrob. Agents Chemother. 36: 87– 91.
56. DuPont, H. L.,, Z. D. Jiang,, C. D. Ericsson,, J. A. Adachi,, J. J. Mathewson,, M. W. DuPont,, E. Palazzini,, L. M. Riopel,, D. Ashley,, and F. Martinez-Sandoval. 2001. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin. Infect. Dis. 33: 1807– 1815.
57. Dutta, D.,, S. K. Bhattacharya,, M. K. Bhattacharya,, A. Deb,, M. Deb,, B. Manna,, A. Moitra,, A. K. Mukhopadhyay,, and G. B. Nair. 1996. Efficacy of norfloxacin and doxycycline for treatment of vibrio cholerae 0139 infection. J. Antimicrob. Chemother. 37: 575– 581.
58. Dutta, P.,, U. Mitra,, S. Dutta,, A. De,, M. K. Chatterjee,, and S. K. Bhattacharya. 2001. Ceftriaxone therapy in ciprofloxacin treatment failure typhoid fever in children. Indian J. Med. Res. 113: 210– 213.
59. Dutta, P.,, R. Rasaily,, M. R. Saha,, U. Mitra,, S. K. Bhattacharya,, M. K. Bhattacharya,, and M. Lahiri. 1993. Ciprofloxacin for treatment of severe typhoid fever in children. Antimicrob. Agents Chemother. 37: 1197– 1199.
60. Echevarria, J.,, C. Seas,, C. Carrillo,, R. Mostorino,, R. Ruiz,, and E. Gotuzzo. 1995. Efficacy and tolerability of ciprofloxacin prophylaxis in adult household contacts of patients with cholera. Clin. Infect. Dis. 20: 1480– 1484.
61. Ellis-Pegler, R. B.,, L. K. Hyman,, R. J. Ingram,, and M. McCarthy. 1995. A placebo controlled evaluation of lomefloxacin in the treatment of bacterial diarrhoea in the community. J. Antimicrob. Chemother. 36: 259– 263.
62. Endtz, H. P.,, R. P. Mouton,, T. van der Reyden,, G. J. Ruijs,, M. Biever,, and B. van Klingeren. 1990. Fluoroquinolone resistance in Campylobacter spp isolated from human stools and poultry products. Lancet 335: 787.
63. Endtz, H. P.,, G. J. Ruijs,, B. van Klingeren,, W. H. Jansen,, T. van der Reyden,, and R. P. Mouton. 1991. Quinolone resistance in Campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J. Antimicrob. Chemother. 27: 199– 208.
64. Engberg, J.,, F. M. Aarestrup,, D. E. Taylor,, P. Gerner-Smidt,, and I. Nachamkin. 2001. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg. Infect. Dis. 7: 24– 34.
65. Ericsson, C. D.,, H. L. DuPont,, and J. J. Mathewson. 1997. Single dose ofloxacin plus loperamide compared with single dose or three days of ofloxacin in the treatment of traveler's diarrhea. J. Travel Med. 4: 3– 7.
66. Ericsson, C. D.,, P. C. Johnson,, H. L. Dupont,, D. R. Morgan,, J. A. Bitsura,, and F. J. de la Cabada. 1987. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial. Ann. Intern. Med. 106: 216– 220.
67. Esposito, S.,, G. B. Gaeta,, D. Galante,, and D. Barba. 1985. Successful treatment with ciprofloxacin of Salmonella typhimurium infection in an immunocompromised host. Infection 13: 288.
68. Essers, B.,, A. P. Burnens,, F. M. Lanfranchini,, S. G. Somaruga,, R. O. von Vigier,, U. B. Schaad,, C. Aebi,, and M. G. Bianchetti. 2000. Acute community-acquired diarrhea requiring hospital admission in Swiss children. Clin. Infect. Dis. 31: 192– 196.
69. Farthing, M.,, R. Feldman,, R. Finch,, R. Fox,, C. Leen,, B. Mandal,, P. Moss,, D. Nathwani,, F. Nye,, A. Percival,, R. Read,, L. Ritchie,, W. T. Todd,, and M. Wood. 1996. The management of infective gastroenteritis in adults. A consensus statement by an expert panel convened by the British Society for the Study of Infection. J. Infect. 33: 143– 152.
70. Felmingham, D.,, and M. J. Robbins. 1992. In vitro activity of lomefloxacin and other antimicrobials against bacterial enteritis pathogens. Diagn. Microbiol. Infect. Dis. 25: 339– 343.
71. Felmingham, D.,, M. J. Robbins,, K. Ingley,, I. Mathias,, H. Bhogal,, A. Leakey,, G. L. Ridgway,, and R. N. Gruneberg. 1997. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J. Antimicrob. Chemother. 39: 43– 49.
72. Fernandez-Roblas, R.,, F. Cabria,, J. Esteban,, J. C. Lopez,, I. Gadea,, and F. Soriano. 2000. In vitro activity of gemifloxacin (SB-265805) compared with 14 other antimicrobials against intestinal pathogens. J. Antimicrob. Chemother. 46: 1023– 1027.
73. Ferreccio, C.,, J. G. Morris, Jr.,, C. Valdivieso,, I. Prenzel,, V. Sotomayor,, G. L. Drusano,, and M. M. Levine 1988. Efficacy of ciprofloxacin in the treatment of chronic typhoid carriers. J. Infect. Dis. 157: 1235– 1239.
74. Frost, J. A.,, A. Kelleher,, and B. Rowe. 1996. Increasing ciprofloxacin resistance in salmonellas in England and Wales 1991-1994. J. Antimicrob. Chemother. 37: 85– 91.
75. Garcia-Rodriguez, J. A.,, M. J. Fresnadillo,, M. I. Garcia,, E. Garcia-Sanchez,, J. E. Garcia-Sanchez,, and I. Trujillano. 1995. Multicenter Spanish study of ciprofloxacin susceptibility in gram-negative bacteria. The Spanish Study Group on Quinolone Resistance. Eur. J. Clin. Microbiol. Infect. Dis. 14: 456– 459.
76. Garcia-Rodriguez, J. A.,, J. E. GarciaSanchez,, M. I. GarciaGarcia,, M. J. Fresnadillo,, I. Trujillano,, and E. GarciaSanchez 1994. In-vitro activity of four new fluoroquinolones. J. Antimicrob. Chemother. 34: 53– 64.
77. Gaudreau, C.,, and H. Gilbert. 1998. Antimicrobial resistance of clinical strains of Campylobacter jejuni subsp. jejuni isolated from 1985 to 1997 in Quebec, Canada. Antimicrob. Agents Chemother. 42: 2106– 2108.
78. Gaunt, P. N.,, and L. J. Piddock. 1996. Ciprofloxacin resistant Campylobacter spp. in humans: an epidemiological and laboratory study. J. Antimicrob. Chemother. 37: 747– 757.
79. Gendrel, D.,, J. L. Moreno,, M. Nduwimana,, C. Baribwira,, and J. Raymond. 1997. One-dose treatment with pefloxacin for infection due to multidrug-resistant Shigella dysenteriae type 1 in Burundi. Clin. Infect. Dis. 24: 83.
80. Gibreel, A.,, E. Sjogren,, B. Kaijser,, B. Wretlind,, and O. Skold. 1998. Rapid emergence of high-level resistance to quinolones in Campylobacter jejuni associated with mutational changes in gyrA and parC. Antimicrob. Agents Chemother. 42: 3276– 3278.
81. Girgis, N. I.,, T. Butler,, R. W. Frenck,, Y. Sultan,, F. M. Brown,, D. Tribble,, and R. Khakhria. 1999. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. Antimicrob. Agents Chemother. 43: 1441– 1444.
82. Glandt, M.,, J. A. Adachi,, J. J. Mathewson,, Z. D. Jiang,, D. DiCesare,, D. Ashley,, C. D. Ericsson,, and H. L. DuPont. 1999. Enteroaggregative Escherichia coli as a cause of traveler's diarrhea: clinical response to ciprofloxacin. Clin. Infect. Dis. 29: 335– 338.
83. Goldstein, F. W.,, J. C. Chumpitaz,, J. M. Guevara,, B. Papadopoulou,, J. F. Acar,, and J. F. Vieu. 1986. Plasmidmediated resistance to multiple antibiotics in Salmonella typhi. J. Infect. Dis. 153: 261– 266.
84. Gomi, H.,, Z. D. Jiang,, J. A. Adachi,, D. Ashley,, B. Lowe,, M. P. Verenkar,, R. Steffen,, and H. L. DuPont. 2001. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. Antimicrob. Agents Chemother. 45: 212– 216.
85. Goodman, L. J.,, R. M. Fliegelman,, G. M. Trenholme,, and R. L. Kaplan. 1984. Comparative in vitro activity of ciprofloxacin against Campylobacter spp. and other bacterial enteric pathogens. Antimicrob. Agents Chemother. 25: 504– 506.
86. Goodman, L. J.,, G. M. Trenholme,, R. L. Kaplan,, J. Segreti,, D. Hines,, R. Petrak,, J. A. Nelson,, K. W. Mayer,, W. Landau,, G. W. Parkhurst, et al. 1990. Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults. Arch. Intern. Med. 150: 541– 546.
87. Goossens, H.,, P. De Mol,, H. Coignau,, J. Levy,, O. Grados,, G. Ghysels,, H. Innocent,, and J. P. Butzler. 1985. Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens. Antimicrob. Agents Chemother. 27: 388– 392.
88. Gorbach, S. L. 1997. Treating diarrhoea. Br. Med. J. 314: 1776– 1777.
89. Gotuzzo, E.,, J. G. Guerra,, L. Benavente,, J. C. Palomino,, C. Carrillo,, J. Lopera,, F. Delgado,, D. R. Nalin,, and J. Sabbaj. 1988. Use of norfloxacin to treat chronic typhoid carriers. J. Infect. Dis. 157: 1221– 1225.
90. Gotuzzo, E.,, R. A. Oberhelman,, C. Maguina,, S. J. Berry,, A. Yi,, M. Guzman,, R. Ruiz,, R. Leon-Barua,, and R. B. Sack. 1989. Comparison of single-dose treatment with norfloxacin and standard 5-day treatment with trimethoprim-sulfamethoxazole for acute shigellosis in adults. Antimicrob. Agents Chemother. 33: 1101– 1104.
91. Gotuzzo, E.,, C. Seas,, J. Echevarria,, C. Carrillo,, R. Mostorino,, and R. Ruiz. 1995. Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults. Clin. Infect. Dis. 20: 1485– 1490.
92. Griffiths, N. M.,, B. H. Hirst,, and N. L. Simmons. 1994. Active intestinal secretion of the fluoroquinolone antibacterials ciprofloxacin, norfloxacin and pefloxacin; a common secretory pathway? J. Pharmacol. Exp. Ther. 269: 496– 502.
93. Gruneberg, R. N.,, D. Felmingham,, M. D. O'Hare,, M. J. Robbins,, K. Perry,, R. A. Wall,, and G. L. Ridgway. 1988. The comparative in-vitro activity of ofloxacin. J. Antimicrob. Chemother. 22: 9– 19.
94. Guerrant, R. L.,, T. Van Gilder,, T. S. Steiner,, N. M. Thielman,, L. Slutsker,, R. V. Tauxe,, T. Hennessy,, P. M. Griffin,, H. DuPont,, R. B. Sack,, P. Tarr,, M. Neill,, I. Nachamkin,, L. B. Reller,, M. T. Osterholm,, M. L. Bennish,, and L. K. Pickering. 2001. Practice guidelines for the management of infectious diarrhea. Clin. Infect. Dis. 32: 331– 351.
95. Hajji, M.,, N. el Mdaghri,, M. Benbachir,, K. M. el Filali,, and H. Himmich. 1988. Prospective randomized comparative trial of pefloxacin versus cotrimoxazole in the treatment of typhoid fever in adults. Eur. J. Clin. Microbiol. Infect. Dis. 7: 361– 363.
96. Hakanen, A.,, P. Kotilainen,, P. Huovinen,, H. Helenius,, and A. Siitonen. 2001. Reduced fluoroquinolone susceptibility in Salmonella enterica serotypes in travelers returning from Southeast Asia. Emerg. Infect. Dis. 7: 996– 1003.
97. Hakanen, A.,, P. Kotilainen,, J. Jalava,, A. Siitonen,, and P. Huovinen. 1999. Detection of decreased fluoroquinolone susceptibility in Salmonellas and validation of nalidixic acid screening test. J. Clin. Microbiol. 37: 3572– 3577.
98. Hakanen, A.,, A. Siitonen,, P. Kotilainen,, and P. Huovinen. 1999. Increasing fluoroquinolone resistance in salmonella serotypes in Finland during 1995-1997. J. Antimicrob. Chemother. 43: 145– 148.
99. Haltalin, K. C.,, J. D. Nelson,, and H. T. Kusmiesz. 1973. Comparative efficacy of nalidixic acid and ampicillin for severe shigellosis. Arch. Dis. Child. 48: 305– 312.
100. Haltalin, K.C.,, J. D. Nelson,, R. Ring III,, M. Sladoje,, and L. V. Hinton. 1967. Double-blind treatment study of shigellosis comparing ampicillin, sulfadiazine, and placebo. J. Pediatr. 70: 970– 981.
101. Hansson, H. B.,, G. Barkenius,, S. Cronberg,, and I. Juhlin. 1981. Controlled comparison of nalidixic acid or lactulose with placebo in shigellosis. Scand. J. Infect. Dis. 13: 191– 193.
102. Hassan, A.,, M. F. Wahab,, Z. Farid,, and A. S. el-Rooby. 1970. Treatment of typhoid and paratyphoid fever with nalidixic acid. J. Trop. Med. Hyg. 73: 145– 147.
103. Heck, J. E.,, J. L. Staneck,, M. B. Cohen,, L. S. Weckbach,, R. A. Giannella,, J. Hawkins,, and R. Tosiello. 1994. Prevention of Travelers' Diarrhea: ciprofloxacin versus trimethoprim/ sulfamethoxazole in adult volunteers working in Latin America and the Caribbean. J. Travel Med. 1: 136– 142.
104. Helms, M.,, P. Vastrup,, P. Gerner-Smidt,, and K. Molbak. 2002. Excess mortality associated with antimicrobial drugresistant Salmonella typhimurium. Emerg. Infect. Dis. 8: 490– 495.
105. Heseltine, P. N.,, D. M. Causey,, M. D. Appleman,, M. L. Corrado,, and J. M. Leedom. 1988. Norfloxacin in the eradication of enteric infections in AIDS patients. Eur. J. Cancer Clin. Oncol. 24: S25– S8.
106. Hoge, C. W.,, J. M. Gambel,, A. Srijan,, C. Pitarangsi,, and P. Echeverria. 1998. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin. Infect. Dis. 26: 341– 345.
107. Hoogkamp-Korstanje, J. A. 1987. Antibiotics in Yersinia enterocolitica infections. J. Antimicrob. Chemother. 20: 123– 131.
108. Hoogkamp-Korstanje, J. A.,, H. Moesker,, and G. A. Bruyn. 2000. Ciprofloxacin v placebo for treatment of Yersinia enterocolitica triggered reactive arthritis. Ann. Rheum. Dis. 59: 914– 917.
109. Hooper, D. C. 2000. New uses for new and old quinolones and the challenge of resistance. Clin. Infect. Dis. 30: 243– 254.
110. Horiuchi, S.,, Y. Inagaki,, N. Yamamoto,, N. Okamura,, Y. Imagawa,, and R. Nakaya. 1993. Reduced susceptibilities of Shigella sonnei strains isolated from patients with dysentery to fluoroquinolones. Antimicrob. Agents Chemother. 37: 2486– 2489.
111. Hung, C. C.,, S. M. Hsieh,, C. F. Hsiao,, M. Y. Chen,, and W. H. Sheng. 2001. Risk of recurrent non-typhoid Salmonella bacteraemia after early discontinuation of ciprofloxacin as secondary prophylaxis in AIDS patients in the era of highly active antiretroviral therapy. AIDS 15: 645– 647.
112. Inglesfield, J. W. 1997. Treating diarrhoea. Advocating widespread use of antimicrobial agents has economic implications. Br. Med. J. 315: 1379.
113. Isenbarger, D. W.,, C. W. Hoge,, A. Srijan,, C. Pitarangsi,, N. Vithayasai,, L. Bodhidatta,, K. W. Hickey,, and P. D. Cam. 2002. Comparative antibiotic resistance of diarrheal pathogens from Vietnam and Thailand, 1996-1999. Emerg. Infect. Dis. 8: 175– 180.
114. Jesudason, M. V.,, B. Malathy,, and T. J. John. 1996. Trend of increasing levels of minimum inhibitory concentration of ciprofloxacin to Salmonella typhi Indian. J. Med. Res. 103: 247– 249.
115. Jiang, Z. D.,, B. Lowe,, M. P. Verenkar,, D. Ashley,, R. Steffen,, N. Tornieporth,, F. von Sonnenburg,, P. Waiyaki,, and H. L. DuPont. 2002. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J. Infect. Dis. 185: 497– 502.
116. Johnson, P. C.,, C. D. Ericsson,, D. R. Morgan,, H. L. Dupont,, and F. J. Cabada. 1986. Lack of emergence of resistant fecal flora during successful prophylaxis of traveler's diarrhea with norfloxacin. Antimicrob. Agents Chemother. 30: 671– 674.
117. Kampfer, P.,, C. Christmann,, J. Swings,, and G. Huys. 1999. In vitro susceptibilities of Aeromonas genomic species to 69 antimicrobial agents. Syst. Appl Microbiol. 22: 662– 669.
118. Kapil, A.,, S. Sood,, N. R. Dash,, B. K. Das,, and P. Seth. 1999. Ciprofloxacin in typhoid fever. Lancet 354: 164.
119. Khan, M. A.,, Z. Hayat,, and A. Sadick. 1994. Ofloxacin in the treatment of typhoid fever resistant to chloramphenicol and amoxicillin. Clin. Ther. 16: 815– 818.
120. Khan, W. A.,, M. Begum,, M. A. Salam,, P. K. Bardhan,, M. R. Islam,, and D. Mahalanabis. 1995. Comparative trial of five antimicrobial compounds in the treatment of cholera in adults. Trans. R. Soc. Trop. Med. Hyg. 89: 103– 106.
121. Khan, W. A.,, M. L. Bennish,, C. Seas,, E. H. Khan,, A. Ronan,, U. Dhar,, W. Busch,, and M. A. Salam. 1996. Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139. Lancet 348: 296– 300.
122. Khan, W. A.,, D. Saha,, A. Rahman,, M. A. Salam,, J. Bogaerts,, and M. L. Bennish. Randomised, double-blinded comparison of single-dose azithromycin and 12 dose, 3-day erythromycin therapy for childhood cholera Lancet, in press.
123. Khan, W. A.,, C. Seas,, U. Dhar,, M. A. Salam,, and M. L. Bennish. 1997. Treatment of shigellosis. V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. Ann. Intern. Med. 126: 697– 703.
124. Kimmitt, P. T.,, C. R. Harwood,, and M. R. Barer. 1999. Induction of type 2 Shiga toxin synthesis in Escherichia coli 0157 by 4-quinolones. Lancet 353: 1588– 1589.
125. Kimmitt, P. T.,, C. R. Harwood,, and M. R. Barer. 2000. Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. Emerg. Infect. Dis. 6: 458– 465.
126. Kubin, R. 1993. Safety and efficacy of ciprofloxacin in paediatric patients—review. Infection 21: 413– 421.
127. Kuschner, R. A.,, A. F. Trofa,, R. J. Thomas,, C. W. Hoge,, C. Pitarangsi,, S. Amato,, R. P. Olafson,, P. Echeverria,, J. C. Sadoff,, and D. N. Taylor. 1995. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. C/m. Infect. Dis. 21: 536– 541.
128. Laing, R. B.,, C. Lee,, and C. L. Leen. 1996. An audit of the clinical features and use of antimicrobials in adult diarrhoea. J. Infect. 32: 17– 21.
129. Leibovitz, E.,, J. Janco,, L. Piglansky,, J. Press,, P. Yagupsky,, H. Reinhart,, I. Yaniv,, and R. Dagan. 2000. Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children. Pediatr. Infect. Dis. J. 19: 1060– 1067.
130. Leigh, D. A.,, B. Walsh,, K. Harris,, P. Hancock,, and G. Travers. 1988. Pharmacokinetics of ofloxacin and the effect on the faecal flora of healthy volunteers. J. Antimicrob. Chemother. 22: 115– 125.
131. Leung, D.,, and P. Venkatesan. 1997. Treating diarrhoea. More evidence is needed that widespread use of quinolones will benefit patients. Br. Med. J. 315: 1379.
132. Liao, W. C.,, and M. S. Cappell. 1989. Treatment with ciprofloxacin of Aeromonas hydrophila associated colitis in a male with antibodies to the human immunodeficiency virus. J. Clin. Gastroenterol. 11: 552– 554.
133. Lindenbaum, J.,, W. B. Greenough,, and M. R. Islam. 1967. Antibiotic therapy of cholera. Bull W. H. O. 36: 871– 883.
134. Lindenbaum, J.,, W. B. Greenough,, and M. R. Islam. 1967. Antibiotic therapy of cholera in children. Bull. W. H. O. 37: 529– 538.
135. Ling, J.,, K. M. Kam,, A. W. Lam,, and G. L. French. 1988. Susceptibilities of Hong Kong isolates of multiply resistant Shigella spp. to 25 antimicrobial agents, including ampicillin plus sulbactam and new 4-quinolones. Antimicrob. Agents. Chemother. 32: 20– 23.
136. Lipsky, B. A.,, and C. A. Baker. 1999. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin. Infect. Dis. 28: 352– 364.
137. Loffler, A.,, and H. Grafvon Westphalen. 1986. Successful treatment of chronic Salmonella excretor with ofloxacin. Lancet 1: 1206.
138. Lolekha, S.,, S. Patanachareon,, B. Thanangkul,, and S. Vibulbandhitkit. 1988. Norfloxacin versus co-trimoxazole in the treatment of acute bacterial diarrhoea: a placebo controlled study. Scand. J. Infect. Dis. Suppl. 56: 35– 45.
139. Lolekha, S.,, S. Vibulbandhitkit,, and P. Poonyarit. 1991. Response to antimicrobial therapy for shigellosis in Thailand. Rev. Infect. Dis. 13: S342– S346.
140. Malorny, B.,, A. Schroeter,, and R. Helmuth. 1999. Incidence of quinolone resistance over the period 1986 to 1998 in veterinary Salmonella isolates from Germany. Antimicrob. Agents Chemother. 43: 2278– 2282.
141. Mandal, B. K.,, M. E. Ellis,, E. M. Dunbar,, and K. Whale. 1984. Double-blind placebo-controlled trial of erythromycin in the treatment of clinical Campylobacter infection. J. Antimicrob. Chemother. 13: 619– 623.
142. Matsushiro, A.,, K. Sato,, H. Miyamoto,, T. Yamamura,, and T. Honda. 1999. Induction of prophages of enterohemorrhagic Escherichia coli 0157:H7 with norfloxacin. J. Bacteriol. 181: 2257– 2260.
143. Mattila, L.,, H. Peltola,, A. Siitonen,, H. Kyronseppa,, I. Simula,, and M. Kataja. 1993. Short-term treatment of traveler's diarrhea with norfloxacin: a double-blind, placebocontrolled study during two seasons. Clin. Infect. Dis. 17: 779– 782.
144. McDermott, P. F.,, S. M. Bodeis,, L. L. English,, D. G. White,, R. D. Walker,, S. Zhao,, S. Simjee,, and D. D. Wagner. 2002. Ciprofloxacin resistance in Campylobacter jejuni evolves rapidly in chickens treated with fluoroquinolones. J. Infect. Dis. 185: 837– 840.
145. Mead, P. S.,, L. Slutsker,, V. Dietz,, L. F. McCaig,, J. S. Bresee,, C. Shapiro,, P. M. Griffin,, and R. V. Tauxe. 1999. Foodrelated illness and death in the United States. Emerg. Infect. Dis. 5: 607– 625.
146. Meskin, S.,, M. S. Jacob,, R. Macaden,, J. S. Keystone,, P. E. Kozarsky,, A. N. Ramachadran,, and B. Metchock. 1992. Short-course treatment of typhoid fever with ciprofloxacin in south India. Trans. R. Soc. Trop. Med. Hyg. 86: 446– 447.
147. Mirelis, B.,, E. Miro,, F. Navarro,, C. A. Ogalla,, J. Bonal,, and G. Prats. 1993. Increased resistance to quinolone in Catalonia, Spain. Diagn. Microbiol. Infect. Dis. 16: 137– 139.
148. Molbak, K.,, D. L. Baggesen,, F. M. Aarestrup,, J. M. Ebbesen,, J. Engberg,, K. Frydendahl,, P. Gerner-Smidt,, A. M. Petersen,, and H. C. Wegener. 1999. An outbreak of multidrug- resistant, quinolone-resistant Salmonella enterica serotype typhimurium DTI 04. N. Engl. J. Med. 341: 1420– 1425.
149. Molbak, K.,, P. Gerner-Smidt,, and H. C. Wegener. 2002. Increasing quinolone resistance in Salmonella enterica serotype Enteritidis. Emerg. Infect. Dis. 8: 514– 515.
150. Moolasart, P.,, B. Eampokalap,, and S. Supaswadikul. 1998. Comparison of the efficacy of tetracycline and norfloxacin in the treatment of acute severe watery diarrhea. Southeast. Asian. } . Trop. Med. Public Health. 29: 108– 111.
151. Moore, J. E.,, M. Crowe,, N. Heaney,, and E. Crothers. 2001. Antibiotic resistance in Campylobacter spp. isolated from human faeces (1980-2000) and foods (1997-2000) in Northern Ireland: an update. J. Antimicrob. Chemother. 48: 455– 457.
152. Murdoch, D. A.,, N. Banatvaia,, A. Bone,, B. I. Shoismatulloev,, L. R. Ward,, E. J. Threlfall,, and N. A. Banatvaia. 1998. Epidemic ciprofloxacin-resistant Salmonella typhi in Tajikistan. Lancet 351: 339.
153. Murphy, G. S.,, L. Bodhidatta,, P. Echeverria,, S. Tansuphaswadikul,, C. W. Hoge,, S. Imlarp,, and K. Tamura. 1993. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann. Intern. Med. 118: 582– 586.
154. Murphy, G. S., Jr.,, P. Echeverria,, L. R. Jackson,, M. K. Arness,, C. LeBron,, and C. Pitarangsi. 1996. Ciprofloxacinand azithromycin-resistant Campylobacter causing traveler's diarrhea in U.S. troops deployed to Thailand in 1994. Clin. Infect. Dis. 22: 868– 869.
155. Murray, B. E.,, T. Alvarado,, K. H. Kim,, M. Vorachit,, P. Jayanetra,, M. M. Levine,, I. Prenzel,, M. Fling,, L. Elwell,, G. H. McCracken, et al. 1985. Increasing resistance to trimethoprim-sulfamethoxazole among isolates of Escherichia coli in developing countries. J. Infect. Dis. 152: 1107– 1113.
156. Musafija, A.,, A. Barzilai,, J. Ramon,, and E. Rubinstein. 1998. Effect of cholera toxin on intestinal elimination of ciprofloxacin in rabbits. Antimicrob. Agents Chemother. 42: 473– 474.
157. Musafija, A.,, J. Ramon,, Y. Shtelman,, G. Yoseph,, B. Rubinovitz,, S. Segev,, and E. Rubinstein. 2000. Trans-epithelial intestinal elimination of moxifloxacin in rabbits. J. Antimicrob. Chemother. 45: 803– 805.
158. Musafija, A.,, Y. Shtelman,, J. Ramon,, M. Volk,, S. Segev,, and E. Rubinstein. 2001. The effect of Escherichia coli heat-stable toxin on the trans-epithelial intestinal elimination of ciprofloxacin in the rabbit. J. Antimicrob. Chemother. 47: 697– 699.
159. Nathwani, D.,, R. B. Laing,, G. Harvey,, and C. C. Smith. 1991. Treatment of symptomatic enteric aeromonas hydrophila infection with ciprofloxacin. Scand. J. Infect. Dis. 23: 653– 654.
160. Neill, M. A.,, S. M. Opal,, J. Heelan,, R. Giusti,, J. E. Cassidy,, R. White,, and K. H. Mayer. 1991. Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers. Ann. Intern. Med. 114: 195– 199.
161. Nelson, M. R.,, D. C. Shanson,, D. A. Hawkins,, and B. G. Gazzard. 1992. Salmonella, Campylobacter and Shigella in HIV-seropositive patients. AIDS 6: 1495– 1498.
162. Nelwan, R. H.,, Hendarwanto,, I. Zulkarnain,, J. Gunawan,, I. Supandiman,, H. Yusuf,, P. Soedjana,, and A. Syahroni. 1995. A comparative study of short course ciprofloxacin treatment in typhoid and paratyphoid fever. Drugs 49: 463– 465.
163. Nguyen, T. C.,, T. Solomon,, X. T. Mai,, T. L. Nguyen,, T. T. Nguyen,, J. Wain,, S. D. To,, M. D. Smith,, N. P. Day,, T. P. Le,, C. Parry,, and N. J. White. 1997. Short courses of ofloxacin for the treatment of enteric fever. Trans. R. Soc. Trop. Med. Hyg. 91: 347– 349.
164. Noguerado, A.,, I. Garcia-Polo,, T. Isasia,, M. L. Jimenez,, P. Bermudez,, J. Pita,, and R. Gabriel. 1995. Early single dose therapy with ofloxacin for empirical treatment of acute gastroenteritis: a randomised, placebo-controlled double-blind clinical trial. J. Antimicrob. Chemother. 36: 665– 672.
165. O'Hare, M. D.,, D. Felmingham,, G. L. Ridgway,, and R. N. Gruneberg. 1985. The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens. Drugs Exp. Clin. Res. 11: 253– 257.
166. Olsen, S. J.,, E. E. DeBess,, T. E. McGivern,, N. Marano,, T. Eby,, S. Mauvais,, V. K. Balan,, G. Zirnstein,, P. R. Cieslak,, and F. J. Angulo. 2001. A nosocomial outbreak of fluoroquinolone- resistant salmonella infection. N. Engl. J. Med. 344: 1572– 1579.
167. Olsson-Liljequist, B.,, and R. Mollby. 1990. In vitro activity of norfloxacin and other antibacterial agents against gastrointestinal pathogens isolated in Sweden. APMIS 98: 150– 155.
168. Parry, C.,, J. Wain,, N. T. Chinh,, H. Vinh,, and J. J. Farrar. 1998. Quinolone-resistant Salmonella typhi in Vietnam. Lancet 351: 1289.
169. Parry, H.,, A. J. Howard,, O. P. Galpin,, and S. P. Hassan. 1994. The prophylaxis of travellers' diarrhoea; a double blind placebo controlled trial of ciprofloxacin during a Himalayan expedition. J. Infect. 28: 337– 338.
170. Pavia, A. T.,, C. R. Nichols,, D. P. Green,, R. V. Tauxe,, S. Mottice,, K. D. Greene,, J. G. Wells,, R. L. Siegler,, E. D. Brewer,, D. Hannon, et al. 1990. Hemolytic-uremic syndrome during an outbreak of Escherichia coli 0157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. J. Pediatr. 116: 544– 551.
171. Pechere, J. C. 1993. Quinolones in intracellular infections. Drugs 45: 29– 36.
172. Pecquet, S.,, A. Andremont,, and C. Tancrede. 1987. Effect of oral ofloxacin on fecal bacteria in human volunteers. Antimicrob. Agents Chemother. 31: 124– 125.
173. Pecquet, S.,, S. Ravoire,, and A. Andremont. 1990. Faecal excretion of ciprofloxacin after a single oral dose and its effect on faecal bacteria in healthy volunteers. J. Antimicrob. Chemother. 26: 125– 129.
174. Petruccelli, B. P.,, G. S. Murphy,, J. L. Sanchez,, S. Walz,, R. DeFraites,, J. Gelnett,, R. L. Haberberger,, P. Echeverria,, and D. N. Taylor. 1992. Treatment of traveler's diarrhea with ciprofloxacin and loperamide. J. Infect. Dis. 165: 557– 560.
175. Pichler, H.,, G. Diridl,, and D. Wolf. 1986. Ciprofloxacin in the treatment of acute bacterial diarrhea: a double blind study. Eur. J. Clin. Microbiol. 5: 241– 243.
176. Pichler, H. E.,, G. Diridl,, K. Stickler,, and D. Wolf. 1987. Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea. Am. J. Med. 82: 329– 332.
177. Piddock, L. J. 1995. Quinolone resistance and Campylobacter spp. J. Antimicrob. Chemother. 36: 891– 898.
178. Pitkajarvi, T.,, E. Kujanne,, I. Sillantaka,, and J. Lumio. 1996. Norfloxacin and Salmonella excretion in acute gastroenteritis— a 6-month follow-up study. Scand. J. Infect. Dis. 28: 177– 180.
179. Pradhan, K. M.,, N. K. Arora,, A. Jena,, A. K. Susheela,, and M. K. Bhan. 1995. Safety of ciprofloxacin therapy in children: magnetic resonance images, body fluid levels of fluoride and linear growth. Acta. Paediatr. 84: 555– 560.
180. Prats, G.,, B. Mirelis,, T. Llovet,, C. Munoz,, E. Miro,, and F. Navarro. 2000. Antibiotic resistance trends in enteropathogenic bacteria isolated in 1985-1987 and 1995-1998 in Barcelona. Antimicrob. Agents Chemother. 44: 1140– 1145.
181. Rademaker, C. M.,, I. M. Hoepelman,, M. J. Wolfhagen,, H. Beumer,, M. Rozenberg-Arska,, and J. Verhoef. 1989. Results of a double-blind placebo-controlled study using ciprofloxacin for prevention of travelers' diarrhea. Eur. J. Clin. Microbiol. Infect. Dis. 8: 690– 694.
182. Ramon, J.,, M. Ben-Haim,, M. Shabtai,, and E. Rubinstein. 2001. Transepithelial intestinal excretion of ciprofloxacin in humans. Clin. Infect. Dis. 32: 822– 823.
183. Ramon, J.,, S. Dautrey,, R. Farinoti,, C. Carbon,, and E. Rubinstein. 1996. Excretion of ciprofloxacin into the large bowel of the rabbit. Antimicrob. Agents Chemother. 40: 11– 13.
184. Ramon, J.,, S. Dautrey,, R. Farinoti,, C. Carbon,, and E. Rubinstein. 1994. Intestinal elimination of ciprofloxacin in rabbits. Antimicrob. Agents Chemother. 38: 757– 760.
185. Rathish, K. C.,, M. R. Chandrashekar,, and C. N. Nagesha. 1995. An outbreak of multidrug resistant typhoid fever in Bangalore. Indian J. Pediatr. 62: 445– 448.
186. Reid, T.,, and C. Smith. 1987. Ciprofloxacin treatment of chronic Salmonella excretors. Chemioterapia 6: 485– 486.
187. Rendi-Wagner, P.,, and H. Kollaritsch. 2002. Drug prophylaxis for travelers' diarrhea. Clin. Infect. Dis. 34: 628– 633.
188. Ries, A. A.,, J. G. Wells,, D. Olivola,, M. Ntakibirora,, S. Nyandwi,, M. Ntibakivayo,, C. B. Ivey,, K. D. Greene,, F. C. Tenover,, S. P. Wahlquist, et al. 1994. Epidemic Shigella dysenteriae type 1 in Burundi: panresistance and implications for prevention. J. Infect. Dis. 169: 1035– 1041.
189. Robins-Browne, R. M.,, M. K. Mackenjee,, M. N. Bodasing,, and H. M. Coovadia. 1983. Treatment of Campylobacterassociated enteritis with erythromycin. Am. J. Dis. Child. 137: 282– 285.
190. Rogerie, F.,, D. Ott,, J. Vandepitte,, L. Verbist,, P. Lemmens,, and I. Habiyaremye. 1986. Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type 1 in adults. Antimicrob. Agents Chemother. 29: 883– 886.
191. Rubinstein, E.,, S. Dautrey,, R. Farinoti,, L. St Julien,, J. Ramon,, and C. Carbon. 1995. Intestinal elimination of sparfloxacin, fleroxacin, and ciprofloxacin in rats. Antimicrob. Agents Chemother. 39: 99– 102.
192. Rubinstein, E.,, L. St Julien,, J. Ramon,, S. Dautrey,, R. Farinotti,, J. F. Huneau,, and C. Carbon. 1994. The intestinal elimination of ciprofloxacin in the rat. J. Infect. Dis. 169: 218– 221.
193. Ruiz, J.,, J. Gomez,, M. M. Navia,, A. Ribera,, J. M. Sierra,, F. Marco,, J. Mensa,, and J. Vila. 2002. High prevalence of nalidixic acid resistant, ciprofloxacin susceptible phenotype among clinical isolates of Escherichia coli and other Enterobacteriaceae. Diagn. Microbiol. Infect. Dis. 42: 257– 261.
194. Ruiz, J.,, P. Goni,, F. Marco,, F. Gallardo,, B. Mirelis,, T. Jimenez De Anta,, and J. Vila. 1998. Increased resistance to quinolones in Campylobacter jejuni: a genetic analysis of gyrA gene mutations in quinolone-resistant clinical isolates. Microbiol. Immunol. 42: 223– 226.
195. Ryan, E. T.,, U. Dhar,, W. A. Khan,, M. A. Salam,, A. S. Faruque,, G. J. Fuchs,, S. B. Calderwood,, and M. L. Bennish. 2000. Mortality, morbidity, and microbiology of endemic cholera among hospitalized patients in Dhaka, Bangladesh. Am. J. Trop. Med. Hyg. 63: 12– 20.
196. Saenz, Y.,, M. Zarazaga,, M. Lantero,, M. J. Gastanares,, F. Baquero,, and C. Torres. 2000. Antibiotic resistance in Campylobacter strains isolated from animals, foods, and humans in Spain in 1997-1998. Antimicrob. Agents Chemother. 44: 267– 271.
197. Salam, I.,, P. Katelaris,, S. Leigh-Smith,, and M. J. Farthing. 1994. Randomised trial of single-dose ciprofloxacin for travellers' diarrhoea. Lancet. 344: 1537– 1539.
198. Salam, M. A.,, and M. L. Bennish. 1991. Antimicrobial therapy for shigellosis. Rev. Infect. Dis. 13: S332– S341.
199. Salam, M. A.,, and M. L. Bennish. 1988. Therapy for shigellosis. I. Randomized, double-blind trial of nalidixic acid in childhood shigellosis. J. Pediatr. 113: 901– 907.
200. Salam, M. A.,, U. Dhar,, W. A. Khan,, and M. L. Bennish. 1998. Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis. Lancet 352: 522– 527.
201. Salazar-Lindo, E.,, R. B. Sack,, E. Chea-Woo,, B. A. Kay,, Z. A. Piscoya,, R. Leon-Barua,, and A. Yi. 1986. Early treatment with erythromycin of Campylobacter jejuni-associated dysentery in children. J. Pediatr. 109: 355– 360.\
202. Sammalkorpi, K.,, J. Lahdevirta,, T. Makela,, and T. Rostila. 1987. Treatment of chronic Salmonella carriers with ciprofloxacin. Lancet 2: 164– 165.
203. San Joaquin, V. H.,, R. K. Scribner,, D. A. Pickett,, and D. F. Welch. 1986. Antimicrobial susceptibility of Aeromonas species isolated from patients with diarrhea. Antimicrob. Agents Chemother. 30: 794– 795.
204. Sanchez, C.,, E. Garcia-Restoy,, J. Garau,, F. Bella,, N. Freixas,, M. Simo,, J. Lite,, P. Sanchez,, E. Espejo,, E. Cobo, et al. 1993. Ciprofloxacin and trimethoprim-sulfamethoxazole versus placebo in acute uncomplicated Salmonella enteritis: a double-blind trial. J. Infect. Dis. 168: 1304– 1307.
205. Sarma, P. S.,, and P. Durairaj. 1991. Randomized treatment of patients with typhoid and paratyphoid fevers using norfloxacin or chloramphenicol. Trans. R. Soc. Trop. Med. Hyg. 85: 670– 671.
206. Scott, D. A.,, R. L. Haberberger,, S. A. Thornton,, and K. C. Hyams. 1990. Norfloxacin for the prophylaxis of travelers' diarrhea in U.S. military personnel. Am. J. Trop. Med. Hyg. 42: 160– 164.
207. Secmeer, G.,, G. Kanra,, G. Figen,, O. Akan,, M. Ceyhan,, and Z. Ecevit. 1997. Ofloxacin versus co-trimoxazole in the treatment of typhoid fever in children. Acta Paediatr. Jpn. 39: 218– 221.
208. Segreti, J.,, T. D. Gootz,, L. J. Goodman,, G. W. Parkhurst,, J. P. Quinn,, B. A. Martin,, and G. M. Trenholme. 1992. Highlevel quinolone resistance in clinical isolates of Campylobacter jejuni. J. Infect. Dis. 165: 667– 670.
209. Shapiro, R. L.,, L. Kumar,, P. Phillips-Howard,, J. G. Wells,, P. Adcock,, J. Brooks,, M. L. Ackers,, J. B. Ochieng,, E. Mintz,, S. Wahlquist,, P. Waiyaki,, and L. Slutsker. 2001. Antimicrobial-resistant bacterial diarrhea in rural western Kenya. J. Infect. Dis. 183: 1701– 1704.
210. Shungu, D. L.,, E. Weinberg,, and H. H. Gadebusch. 1983. In vitro antibacterial activity of norfloxacin (MK-0366, AM- 715) and other agents against gastrointestinal tract pathogens. Antimicrob. Agents Chemother. 23: 86– 90.
211. Sjogren, E.,, G. B. Lindblom,, and B. Kaijser. 1997. Norfloxacin resistance in Campylobacter jejuni and Campylobacter coli isolates from Swedish patients. J. Antimicrob. Chemother. 40: 257– 261.
212. Slutsker, L.,, A. A. Ries,, K. Maloney,, J. G. Wells,, K. D. Greene,, and P. M. Griffin. 1998. A nationwide case-control study of Escherichia coli 0157:H7 infection in the United States. J. Infect. Dis. 177: 962– 966.
213. Smith, K. E.,, J. M. Besser,, C. W. Hedberg,, F. T. Leano,, J. B. Bender,, J. H. Wicklund,, B. P. Johnson,, K. A. Moore,, and M. T. Osterholm. 1999. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation Team. N. Engl. J. Med. 340: 1525– 1532.
214. Smith, M. D.,, N. M. Duong,, N. T. Hoa,, J. Wain,, H. D. Ha,, T. S. Diep,, N. P. Day,, T. T. Hien,, and N. J. White. 1994. Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever. Antimicrob. Agents Chemother. 38: 1716– 1720.
215. Steffen, R.,, R. Jori,, H. L. DuPont,, J. J. Mathewson,, and D. Sturchler. 1993. Efficacy and toxicity of fleroxacin in the treatment of travelers' diarrhea. Am. J. Med. 94: 182S– 186S.
216. Stephens, I.,, and M. M. Levine. 2002. Management of typhoid fever in children. Pediatr. Infect. Dis. J. 21: 157– 158.
217. Stock, I.,, B. Henrichfreise,, and B. Wiedemann. 2002. Natural antibiotic susceptibility and biochemical profiles of Yersinia enterocolitica-like strains: Y. bercovieri, Y. mollaretii, Y. aldovae and 'Y. ruckeri.' J. Med. Microbiol. 51: 56– 69.
218. Stock, I.,, and B. Wiedemann. 2001. Natural antimicrobial susceptibilities of Plesiomonas shigelloides strains. J. Antimicrob. Chemother. 48: 803– 811.
219. Stolk-Engelaar, V. M.,, J. F. Meis,, J. A. Mulder,, F. L. Loeffen,, and J. A. Hoogkamp-Korstanje. 1995. In-vitro antimicrobial susceptibility of Yersinia enterocolitica isolates from stools of patients in The Netherlands from 1982-1991. J. Antimicrob. Chemother. 36: 839– 843.
220. Taylor, D. N.,, J. L. Sanchez,, W. Candler,, S. Thornton,, C. McQueen,, and P. Echeverria. 1991. Treatment of travelers' diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone. A placebo-controlled, randomized trial. Ann. Intern. Med. 114: 731– 734.
221. Taylor, S. J. 1997. Treating diarrhoea. Proposals are irresponsible and impractical. Br. Med. J . 315: 1377– 1378.
222. Thomas, M. E.,, and N. Datta. 1969. Emergence of Shigella sonnei resistant to kanamycin and to nalidixic acid, without exposure to these drugs. J. Med. Microbiol. 2: 457– 461.
223. Thomsen, L. L.,, and A. Paerregaard. 1998. Treatment with ciprofloxacin in children with typhoid fever. Scand. J. Infect. Dis. 30: 355– 357.
224. Thornton, S. A.,, S. F. Wignall,, M. E. Kilpatrick,, A. L. Bourgeois,, C. Gardiner,, R. A. Batchelor,, D. H. Burr,, J. J. Oprandy,, P. Garst,, and K. C. Hyams. 1992. Norfloxacin compared to trimethoprim/sulfamethoxazole for the treatment of travelers' diarrhea among U.S. military personnel deployed to South America and West Africa. Mil. Med. 157: 55– 5S.
225. Threlfall, E. J.,, A. Graham,, T. Cheasty,, L. R. Ward,, and B. Rowe. 1997. Resistance to ciprofloxacin in pathogenic Enterobacteriaceae in England and Wales in 1996. J. Clin. Pathol. 50: 1027– 1028.
226. Threlfall, E. J.,, and L. R. Ward. 2001. Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype typhi, United Kingdom. Emerg. Infect. Dis. 7: 448– 450.
227. Threlfall, E. J.,, L. R. Ward,, J. A. Skinner,, H. R. Smith,, and S. Lacey. 1999. Ciprofloxacin-resistant Salmonella typhi and treatment failure. Lancet 353: 1590– 1591.
228. Thwaites, R. T.,, and J. A. Frost. 1999. Drug resistance in Campylobacter jejuni, C coli, and C lari isolated from humans in north west England and Wales, 1997. J. Clin. Pathol. 52: 812– 814.
229. Tran, T. H.,, D. B. Bethell,, T. T. Nguyen,, J. Wain,, S. D. To,, T. P. Le,, M. C. Bui,, M. D. Nguyen,, T. T. Pham,, A. L. Walsh, et al. 1995. Short course of ofloxacin for treatment of multidrug-resistant typhoid. Clin. Infect. Dis. 20: 917– 923.
230. Tran, T. H.,, M. D. Nguyen,, D. H. Huynh,, T. T. Nguyen,, S. D. To,, T. P. Le,, and K. Arnold. 1994. A randomized comparative study of fleroxacin and ceftriaxone in enteric fever. Trans. R. Soc. Trop. Med. Hyg. 88: 464– 465.
231. Truong, Q. C, S. Ouabdesselam, D. C. Hooper, N. J. Moreau, and C. J. Soussy. 1995. Sequential mutations of gyrA in Escherichia coli associated with quinolone therapy. J. Antimicrob. Chemother. 36: 1055– 1059.
232. Unal, S.,, M. Hayran,, S. Tuncer,, D. Gur,, O. Uzun,, M. Akova,, and H. E. Akalin. 1996. Treatment of enteric fever with pefloxacin for 7 days versus 5 days: a randomized clinical trial. Antimicrob. Agents Chemother. 40: 2898– 2900.
233. Usubutun, S.,, C. Agalar,, C. Diri,, and R. Turkyilmaz. 1997. Single dose ciprofloxacin in cholera. Eur. J. Emerg. Med. 4: 145– 149.
234. Uwaydah, A. K.,, H. al Soub,, and I. Matar. 1992. Randomized prospective study comparing two dosage regimens of ciprofloxacin for the treatment of typhoid fever. J. Antimicrob. Chemother. 30: 707– 711.
235. Van Looveren, M.,, G. Daube,, L. De Zutter,, J. M. Dumont,, C. Lammens,, M. Wijdooghe,, P. Vandamme,, M. Jouret,, M. Cornelis,, and H. Goossens. 2001. Antimicrobial susceptibilities of Campylobacter strains isolated from food animals in Belgium. J. Antimicrob. Chemother. 48: 235– 240.
236. Vanhoof, R.,, J. M. Hubrechts,, E. Roebben,, H. J. Nyssen,, E. Nulens,, J. Leger,, and N. De Schepper. 1986. The comparative activity of pefloxacin, enoxacin, ciprofloxacin and 13 other antimicrobial agents against enteropathogenic microorganisms. Infection. 14: 294– 298.
237. Velmonte, M. A.,, and C. S. Montalban. 1988. Norfloxacin in the treatment of infections caused by Salmonella typhi. Scand. J. Infect. Dis. Suppl. 56: 46– 48.
238. Verdier, R. I.,, D. W. Fitzgerald,, W. D. Johnson, Jr.,, and J. W. Pape. 2000. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann. Intern. Med. 132: 885– 888.
239. Vila, J.,, J. Gascon,, S. Abdalla,, J. Gomez,, F. Marco,, A. Moreno,, M. Corachan,, and T. Jimenez de Anta. 1994. Antimicrobial resistance of Shigella isolates causing traveler's diarrhea. Antimicrob. Agents Chemother. 38: 2668– 2670.
240. Vila, J.,, M. Vargas,, C. Casals,, H. Urassa,, H. Mshinda,, D. Schellemberg,, and J. Gascon. 1999. Antimicrobial resistance of diarrheagenic Escherichia coli isolated from children under the age of 5 years from Ifakara, Tanzania. Antimicrob. Agents Chemother. 43: 3022– 3024.
241. Vila, J.,, M. Vargas,, J. Ruiz,, M. Corachan,, M. T. Jimenez De Anta,, and J. Gascon. 2000. Quinolone resistance in enterotoxigenic Escherichia coli causing diarrhea in travelers to India in comparison with other geographical areas. Antimicrob. Agents Chemother. 44: 1731– 1733.
242. Vila, J.,, M. Vargas,, J. Ruiz,, M. Espasa,, M. Pujol,, M. Corachan,, M. T. Jimenez de Anta,, and J. Gascon. 2001. Susceptibility patterns of enteroaggregative Escherichia coli associated with traveller's diarrhoea: emergence of quinolone resistance. J. Med. Microbiol. 50: 996– 1000.
243.